<DOC>
	<DOCNO>NCT00003086</DOCNO>
	<brief_summary>RATIONALE : Bone marrow transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase I/II trial study effectiveness repeat use high-dose chemotherapy plus bone marrow transplantation samarium 153 treat woman stage IV breast cancer .</brief_summary>
	<brief_title>Repeated Bone Marrow Transplantation Treating Women With Advanced Breast Cancer</brief_title>
	<detailed_description>OBJECTIVES : I . Determine maximum tolerate dose ( MTD ) samarium 153 use sequentially autologous bone marrow transplantation metastatic breast cancer . II . Determine response rate , median duration response , overall survival patient respond induction therapy follow 2 cycle high dose chemotherapy stem cell support . OUTLINE : This dose escalation study . Patients first treat salvage chemotherapy 4 cycle . At least partial remission must achieve . Peripheral blood stem cell ( PBSC ) collect follow administration filgrastim ( granulocyte colony-stimulating factor ; G-CSF ) . After recovery prior chemotherapy , high dose chemotherapy begin . Paclitaxel administer 24 hour infusion day -7 . Melphalan IV administer 1 hour day -6 -5 . PBSC infuse day 0 . A second regimen high dose chemotherapy begin least 42 day posttransplant long least partial remission occur previous chemotherapy . Samarium 153 administer day -14 . Cohorts 3 patient treat dose level maximum tolerate dose reach ( define dose dose limit toxicity occur 3 6 patient ) . Cyclophosphamide , thiotepa , carboplatin infuse 24 hour day -7 -4 . PBSC infuse day 0 follow G-CSF IV . The phase II dose samarium 153 one dose level MTD determine Phase I portion study . Patients follow death . PROJECTED ACCRUAL : At least 12 patient accrue study .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Fluorouracil</mesh_term>
	<mesh_term>Thiotepa</mesh_term>
	<mesh_term>Melphalan</mesh_term>
	<mesh_term>Ifosfamide</mesh_term>
	<mesh_term>Liposomal doxorubicin</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Doxorubicin</mesh_term>
	<mesh_term>Samarium ethylenediaminetetramethylenephosphonate</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven metastatic breast cancer Adequate peripheral blood stem cell harvest stored PATIENT CHARACTERISTICS : Age : 2165 Sex : Female Performance status : 01 Life expectancy : Not specify Hematopoietic : Not specify Hepatic : Bilirubin le 1.5 mg/dL SGOT SGPT normal Renal : Creatinine le 1.5 mg/dL Cardiovascular : Ejection fraction least 50 % No symptomatic coronary artery disease Pulmonary : FEV1 DLCO great 50 % predict Other : Not pregnant Not HIV positive Not hepatitis B surface antigen positive No uncontrolled infection No prior malignancy within 5 year except : Curatively treat situ adenocarcinoma cervix Curatively treat nonmelanoma skin cancer PRIOR CONCURRENT THERAPY : Recovered toxic effect prior therapy Biologic therapy : Not specify Chemotherapy : No prior chemotherapy metastatic disease Prior adjuvant chemotherapy allow Endocrine therapy : Not specify Radiotherapy : No prior radiotherapy metastatic disease Surgery : Not specify</criteria>
	<gender>Female</gender>
	<minimum_age>21 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>December 2006</verification_date>
	<keyword>stage IV breast cancer</keyword>
</DOC>